Wendy van Hemmen | Ubiquitous Pharmacogenomics (U-PGx)

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programmes have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Continue reading →

Author: Wendy van Hemmen

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. Samwald M, Xu H, Blagec K, Empey PE, Malone DC, Ahmed SM, Ryan P, Hofer S, Boyce RD. PLoS One. 2016 Oct 20;11(10):e0164972.

The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Lauschke VM, Ingelman-Sundberg M. Int J Mol Sci. 2016 Oct 12;17(10).

Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Nies AT, Damme K, Kruck S, Schaeffeler E, Schwab M. Arch Toxicol. 2016 Jul;90(7):1555-84.

DNA Methylation of ADME Genes. Fisel P, Schaeffeler E, Schwab M. Clin Pharmacol Ther. 2016 May;99(5):512-27.

Be ready to include the first patients!

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Ethical approval at 4 clinical sites

First ethical approval PREPARE study protocol

PREPARE protocol submitted by all 7 sites

Protocol submitted in 2 more countries